Agrimonolide inhibits cancer progression and induces ferroptosis and apoptosis by targeting SCD1 in ovarian cancer cells

Background: Ovarian cancer is a gynaecological tumour has high incidence and mortality rates. Agrimonolide, isolated from Agrimonia pilosa Ledeb, has multiple biomedical activities, including anticancer activity. Purpose: Here, we aimed to reveal the function of agrimonolide on ovarian cancer progression. Methods: MTT assay, colony-formation assay, flow cytometry, transwell assay, scratch test, western immunoblotting, reactive oxygen species (ROS) detection, and ferroptosis analysis were performed to reveal the role and underlying mechanisms of agrimonolide in ovarian cancer cell lines (A2780 and SKOV-3). The effects of agrimonolide on the SKOV-3 xenograft model were also studied. Results: Agrimonolide dose-dependently inhibited proliferation, migration, and invasion and promoted apoptosis in A2780 and SKOV-3 cells. Agrimonolide induced ferroptosis in tumour cells, evidenced by the increased levels of ROS, total iron, and Fe2+ and downregulation of ferroptosis indicators (SLC7A11 and GPX4). The SwissTargetPrediction and Comparative Toxicogenomics Database predicted SCD1 as a target protein for agrimonolide. Molecular Operating Environment software docked agrimonolide in the SCD1 protein, and the binding energy of interaction was -8.21 kcal/mol. The effects of agrimonolide on proliferation, invasion, and induction of apoptosis and ferroptosis were attenuated by SCD1 overexpression in A2780 and SKOV-3 cells. Additionally, agrimonolide attenuated the tumour growth of ovarian cancer in the SKOV-3 xenograft model and significantly downregulated SCD1 in tumour tissues. Conclusion: Our study is the first to suggest that agrimonolide acts as a novel apoptosis-and ferroptosis-inducing agent in ovarian cancer cells by targeting SCD1. Agrimonolide may be a novel therapeutic agent for treating ovarian cancer.

Automated summary

Agrimonolide induces apoptosis and ferroptosis by targeting SCD1 in ovarian cancer cells, demonstrating its anticancer activity. Agrimonolide may serve as a novel therapeutic agent for treating ovarian cancer.